Table 1.
General characteristics.
| Demographics and clinical data at baseline | |
| Age | 51.8 ± 8.9 |
| Body mass index, kg/m2 | 26.9 ± 3.6 |
| Body surface area, m2 | 1.8 ± 0.1 |
| Heart rate | 72 ± 11 |
| Hypertension, %, (N) | 22.2 (6) |
| Diabetes, %, (N) | 0 (0) |
| Hyperlipidemia, % (N) | 14.8 (4) |
| Tobacco current use, %, (N) | 22.2 (6) |
| Former smoker, %, (N) | 11.1 (3) |
| Framingham 10-year risk for a CVD event, % (range) | 5 (1.4–21.1) |
| The Framingham age adjusted risk increment, % (range) | 2.9 (0–17.7) |
| Medication use | |
| Angiotensin-converting enzyme inhibitor, %, (N) | 14.8 (4) |
| Aspirin, %, (N) | 3.7 (1) |
| β-Blocker, %, (N) | 3.7 (1) |
| Statin, %, (N) | 14.8 (4) |
| Metformin, %, (N) | 0 (0) |
| Insulin, %, (N) | 0 (0) |
| Laboratory analyses | |
| HDL-cholesterol, mg/dl | 59 ± 14.9 |
| LDL-cholesterol, mg/dl | 144 ± 28 |
| Triglycerides, mg/dl | 120 ± 35 |
| CRP levels, mg/l | 0.3 ± 0.2 |
| Glucose, mg/dl | 89 ± 12.9 |
| Glycated hemoglobin, % | 5.5 ± 0.3 |
| White blood cells, 103/mm3 | 6.1 ± 0.9 |
| Glomerular filtration rate, ml/min/1.73 m2 | 125 ± 35 |
Data are presented as mean ± SD, n (%) or median (range) when appropriated. CVD cardiovascular disease.